AR123730A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- AR123730A1 AR123730A1 ARP210102801A ARP210102801A AR123730A1 AR 123730 A1 AR123730 A1 AR 123730A1 AR P210102801 A ARP210102801 A AR P210102801A AR P210102801 A ARP210102801 A AR P210102801A AR 123730 A1 AR123730 A1 AR 123730A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- och3
- independently selected
- tau protein
- tau
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 102000013498 tau Proteins Human genes 0.000 abstract 4
- 108010026424 tau Proteins Proteins 0.000 abstract 4
- 125000006519 CCH3 Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 102000004243 Tubulin Human genes 0.000 abstract 2
- 108090000704 Tubulin Proteins 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 230000002776 aggregation Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035474 group of disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Abstract
La presente invención se refiere a compuestos novedosos que se pueden emplear en el tratamiento, alivio o prevención de un grupo de enfermedades, trastornos y/o anomalías asociadas con el plegamiento incorrecto de la proteína Tau y/o agregación patológica de la proteína Tau (unidad asociada a tubulina) que incluye, entre otros, los ovillos neurofibrilares (NFT), tal como la enfermedad de Alzheimer (AD). La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos, métodos que utilizan dichos compuestos, combinaciones que comprenden dichos compuestos, medicamentos que los contienen, y sus usos en enfermedades, trastornos y/o anomalías asociadas con el plegamiento incorrecto de proteína Tau y/o la agregación patológica de proteína Tau (unidad asociada a tubulina). Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, en donde Y es S u O; R¹ es un heterociclilo mono o bicíclico; Q¹ y Q⁴ son diferentes y se seleccionan independientemente de CH y N; Q² y Q³ son diferentes y se seleccionan independientemente de N, C y C-L-R², en donde al menos uno de Q² o Q³ es C-L-R²; L es -NH(CO)-, C₂₋₄alquinilo, -NH-; o L es un heteroarilo; o L es un heterociclilo saturado o insaturado de 5 a 8 miembros opcionalmente sustituido con halo o alquilo C₁₋₄; o L es un enlace; R² se selecciona de los compuestos del grupo de fórmulas (2), en donde R es alquilo C₁₋₄ o H; Z¹ es N, CH, C-F, y C-OCH₃; Z¹ es N, CH, C-F, C-CH₃, y C-OCH₃; Z² es N, CH, C-F, C-CH₃, y C-OCH₃; Z³ o Z⁴ se seleccionan independientemente de N, CH, C-F y C-CH₃; y en donde cuando Z⁴ es N, al menos uno de Z¹, Z¹, Z², Z³ es C-F.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063092105P | 2020-10-15 | 2020-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123730A1 true AR123730A1 (es) | 2023-01-04 |
Family
ID=78212109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102801A AR123730A1 (es) | 2020-10-15 | 2021-10-07 | Compuestos novedosos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230391774A1 (es) |
| EP (1) | EP4229052A1 (es) |
| JP (1) | JP2023546094A (es) |
| CN (1) | CN116568684A (es) |
| AR (1) | AR123730A1 (es) |
| CA (1) | CA3195535A1 (es) |
| WO (1) | WO2022078971A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525226A (ja) | 2002-12-24 | 2006-11-09 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| KR102646115B1 (ko) * | 2016-03-11 | 2024-03-12 | 에이씨 이뮨 에스에이 | 진단 및 치료를 위한 바이사이클릭 화합물 |
| US10633383B2 (en) * | 2018-01-05 | 2020-04-28 | Ac Immune Sa | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates |
| CA3131805C (en) * | 2019-03-01 | 2023-11-21 | Ac Immune Sa | Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates |
-
2021
- 2021-10-07 AR ARP210102801A patent/AR123730A1/es unknown
- 2021-10-11 US US18/248,195 patent/US20230391774A1/en active Pending
- 2021-10-11 WO PCT/EP2021/078079 patent/WO2022078971A1/en active Application Filing
- 2021-10-11 CA CA3195535A patent/CA3195535A1/en active Pending
- 2021-10-11 EP EP21793893.5A patent/EP4229052A1/en active Pending
- 2021-10-11 JP JP2023522953A patent/JP2023546094A/ja active Pending
- 2021-10-11 CN CN202180084367.4A patent/CN116568684A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022078971A1 (en) | 2022-04-21 |
| JP2023546094A (ja) | 2023-11-01 |
| CA3195535A1 (en) | 2022-04-21 |
| TW202231272A (zh) | 2022-08-16 |
| US20230391774A1 (en) | 2023-12-07 |
| CN116568684A (zh) | 2023-08-08 |
| EP4229052A1 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012324803B9 (en) | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | |
| JP2017075155A (ja) | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 | |
| PE20220140A1 (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos | |
| CL2018000036A1 (es) | Derivados etinilo | |
| WO2020176599A1 (en) | Azepino-indoles and other heterocycles for treating brain disorders | |
| EP2701699A1 (en) | Inhibitors of histone deacetylase | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR039566A1 (es) | Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion | |
| ECSP13012858A (es) | Derivados de piperidina puenteada | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR110122A1 (es) | Fenoxitriazoles | |
| WO2019244002A1 (en) | Pyridinyl pyrazoles as modulators of roryt | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| WO2005030188A2 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
| AR117835A1 (es) | Complejo diastereoisomérico enriquecido de gadolinio y de un ligando quelante a base de pcta, y proceso de preparación y purificación del mismo | |
| US20190382354A1 (en) | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) | |
| AR118082A1 (es) | Inhibidores de enzimas | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| AR123730A1 (es) | Compuestos novedosos | |
| EP0492136A2 (en) | Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene | |
| PE20160898A1 (es) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos | |
| AR037250A1 (es) | Compuesto de 1h-quinolin-2-ona sustituido, proceso para su preparacion, medicamento que lo comprende y su uso en la fabricacion de un medicamento | |
| US2454746A (en) | Cyclohexylalkylamines |